Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

625

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

March 25, 2022

Study Completion Date

January 22, 2026

Conditions
Lyme Borreliosis
Interventions
BIOLOGICAL

VLA15

a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate

BIOLOGICAL

Placebo

PBS (Phosphate Buffered Saline)

Trial Locations (22)

10314

Richmond Behavioral Associates, Staten Island

10467

Advantage Clinical Trials, The Bronx

10965

Pfizer Vaccine Research and Development, Pearl River

12247

Synevo Studien Service Labor GmbH c/o Institut für Medizinische Diagnostik, Berlin

13905

Meridian Clinical Research LLC, Binghamton

14609

Rochester Clinical Research, Inc., Rochester

16506

Allegheny Health and Wellness Pavilion, Erie

16508

Liberty Family Practice, Erie

19034

Lockman & Lubell Pediatric Associates, Fort Washington

44122

Velocity Clinical Research, Inc., Cleveland

55402

Clinical Research Institute, Inc., Minneapolis

06606

New England Research Associates, Bridgeport

06905

Stamford Therapeutics Consortium, Stamford

06708

Chase Medical Research, LLC, Waterbury

Pediatric Associates of Conn. PC, Waterbury

01752

Quest Diagnostics, Marlborough

07018

Foundation Pediatrics, East Orange

07111

Med Clinical Research Partners, LLC, Irvington

02903

Hasbro Children's Hospital, Providence

Rhode Island Hospital, Providence

02906

The Miriam Hospital, Providence

02886

Velocity Clinical Research Providence, Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Valneva Austria GmbH

INDUSTRY

lead

Pfizer

INDUSTRY